tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Scott McAuley

Scott McAuley

Paradigm
Wall Street Analyst
Ranked #6,334 out of 8,047 Analysts on TipRanks (#16,826 out of 21,521 overall experts)

Success Rate

46%
6 out of 13 Profitable Transactions

Average Return

-5.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Scott McAuley's ratings since 2021 and opened each position for the duration of 1 Year:
46.15% of your transactions would have been profitable with an average return of -5.7%

Stock Rating Distribution

13Ratings
100.00% Buy
0.00% Hold
0.00% Sell
Distribution of Scott McAuley's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
CanadaCanadian Market

Best Rating

Stock:
Spectral Medical (Edtxf)
(EDTXF)
Rating Type:Buy
Dates:Apr 07, 2022 - Jan 01, 1970
Gain:44.40%
The most profitable rating made by Scott McAuley

Scott McAuley's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
NervGen Pharma
Oct 13, 2021
Buy
Initiated
$4.07
(163.82% Upside)
0%
-19.60%
1
Knight Therapeutics
Feb 03, 2022
Buy
Reiterated
$5.87
(25.20% Upside)
100%
+10.75%
2
Valeo Pharma
Feb 03, 2022
Buy
Reiterated
$1.80
(264.70% Upside)
0%
-16.70%
2
Zymeworks
Feb 09, 2022
Buy
Reiterated
$24.00
(223.01% Upside)
33%
-20.90%
3
Spectral Medical
Apr 07, 2022
Buy
Reiterated
100%
+44.40%
1
Opsens Inc
Apr 14, 2022
Buy
Reiterated
C$3.75
(43.13% Upside)
100%
+26.50%
1
Perimeter Medical Imaging AI
Apr 21, 2022
Buy
Reiterated
C$5.20
(181.08% Upside)
0%
-29.55%
2
Antibe Therapeutics
Jul 04, 2022
Buy
Reiterated
$1.25
(151.31% Upside)
100%
+7.50%
1
List of latest recommendations made by Scott McAuley. Click to expand and see Scott McAuley's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More